Slide 1: Investor Presentation
Investor Presentation July 2026
Slide 2: Forward-looking statements
This presentation contains forward-looking statements within the meaning of the Private Securities litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words suc
Slide 3: Our Vision: Transform cataract surgery outcomes via adjustability
OUR VISION Transform cataract surgery outcomes via the power of adjustability
Slide 4: Adjustability is Becoming a Foundation of Premium Outcomes
Adjustability is Becoming a Foundation of Premium Outcomes Adjustability Offers: • Targeted refractive accuracy Quality of Vision • Customization to patient lifestyle Adjustability • High patient satisfaction and confidence Range of Vision
Slide 5: The Ability to Adjust the Lens After Surgery Delivers Unmatched Refractive Precision
The Ability to Adjust the Lens After Surgery Delivers Unmatched Refractive Precision LAL eyes have 14.5 X better odds of achieving optimal visual outcomes (absolute MRSE and MRCyl ≤ 0.50 D)1 Other Lenses LAL 1. Data on file - RxSight Post-Approval Study
Slide 6: Developing First and Only Suite of Adjustable IOLs
Developing First and Only Suite of Adjustable IOLs Improved Workflow with Fewer Required Visits Expanded Patient Choice Leverages Adjustability Infrastructure Next-Gen LAL Next-Gen LAL+ LAL Toric Astigmatism-Correcting Astigmatism Correcting Astigmatism Built-in Alcon Collaboration Products Monofoca
Slide 7: Partnership Scope and Key Terms
7 RxSight Alcon Collaboration Collaboration Products Simultaneous Vision Intraocular Lenses (“SVIOLs”) Scope License Non-Exclusive Partnership Scope and Key Terms Term 10 years from first commercial sale; autorenewal for additional 5-year terms Upfront 1 $ 60m Economic Terms Additional Milestones 1
Slide 8: Growing Data Set and Clinical Consensus
Growing Data Set and Clinical Consensus Real world data from over 7,000 eyes LAL Customer Survey ACCURACY BINOCULAR QUALI TY PREFERENCE OUTCOMES >94% >90% 90% 79% +/- MRSE 1 believe LAL provides would select for their 20/25 distance and highest quality of own premium IOL J2 near without vision 2 sur
Slide 9: Adjustability Drives Superior Practice Economics
Boosting profitability through premium IOL adoption Adjustability Drives Superior Practice Economics Expand the Premium Market Command a Premium Price Unify the Care Team $2,064 1 Data shows 40% of LAL Patients demonstrate a Enables both surgeons Average additional patients would have high willingne
Slide 10: Scaling Adjustability Worldwide
Scaling Adjustability Worldwide MARKETS STRATEGY 10 approved markets Focus on Top Lean, Scalable Go-to- across three global regions Premium Markets Market NORTH AMERICA Prioritizing entry into the largest Direct model in high-volume United States of the world's top-20 premium markets; hub-and-spoke
Slide 11: A well-established commercial platform validated by a large installed base
A well-established commercial platform validated by a large installed base LAL Units LDD Installed Base 109,615 1,134 98,055 971 666 54,873 400 25,284 206 4,471 8,328 92 2020 2021 2022 2023 2024 2025 2020 2021 2022 2023 2024 2025 Total Revenue (in millions) $139.9 $134.5 $89.1 $49.0 $22.6 $14.7 2020
Slide 12: $32M-$34M Total Company Revenue
$32M-$34M 1,100 + 24,917 Total Company Ophthalmic LALs Sold Revenue2 Offices With LDDs 1,166 $209M LDD Installed Base3 Cash, Cash Equivalents & ST Investments 1. Financial and operating results are preliminary estimates. Actual results remain subject to completion of financial statements and review
Slide 13: Adjustability Wins Long-Term
Adjustability Wins Long-Term RxSight offers the only Adjustable IOL Platform Differentiated Expanding Global Strong Balance Platform Pipeline Expansion Sheet
Slide 14: Thank You
RxSIGHT Thank You